Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors

NCT01262235 is registered in ClinicalTrials.gov with Arbutus Biopharma Corporation as lead sponsor.

NCT NCT01262235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01262235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Lead sponsor
Arbutus Biopharma Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2010
Completion date
August 31, 2015
Enrollment
68 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acc, adrenocortical carcinoma, cancer, net, neuroendocrine tumors